[1] [1] Huang, Z., “A review of progress in clinical photodynamic therapy,” Tech. Cancer Res. Treat. 4, 283–293 (2005).

[2] [2] Qiang, Y. G., Zhang, X. P., Li, J. and Huang, Z., “Photodynamic therapy for malignant and nonmalignant diseases: Clinical investigation and application,” Chin. Med. J. (Engl.). 119, 845–857 (2006).

[3] [3] Veien, N. K., Genner, J., Brodthagen, H. and Wettermark, G., “Photodynamic inactivation of verrucae vulgares. II,” Acta Derm. Venereol. 57, 445–447 (1977).

[4] [4] Dougherty, T. J., Kaufman, J. E., Goldfarb, A., Weishaupt, K. R., Boyle, D. and Mittleman, A., “Photoradiation therapy for the treatment of malignant tumors,” Cancer Res. 38, 2628–2635 (1978).

[5] [5] Dougherty, T. J., Lawrence, G., Kaufman, J. H., Boyle, D., Weishaupt, K. R. and Goldfarb, A., “Photoradiation in the treatment of recurrent breast carcinoma,” J. Natl. Cancer Inst. 62, 231– 237 (1979).

[6] [6] Oseroff, A. R., Blumenson, L. R., Wilson, B. D., Mang, T. S., Bellnier, D. A., Parsons, J. C., Frawley, N., Cooper, M., Zeitouni, N. and Dougherty, T. J., “A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma,” Lasers Surg. Med. 38, 417– 426 (2006).

[7] [7] Kennedy, J. C., Pottier, R. H. and Pross, D. C., “Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience,” J. Photochem. Photobiol. B. 6, 143– 148 (1990).

[8] [8] Tschen, E. H., Wong, D. S., Pariser, D. M., Dunlap, F. E., Houlihan, A., Ferdon, M. B. and Phase IV ALA-PDT Actinic Keratosis Study Group, “Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: Phase IV multicentre clinical trial with 12-month follow up,” Br. J. Dermatol. 155, 1262–1269 (2006).

[9] [9] Stables, G. I., Stringer, M. R., Robinson, D. J. and Ash, D. V., “Large patches of Bowen’s disease treated by topical aminolaevulinic acid photodynamic therapy,” Br. J. Dermatol. 136, 957–960 (1997).

[10] [10] Wang, X. L., Xu, S. Z., Zhang, C. R. and Zheng, W., “Photodynamic therapy of Bowen’s disease using 5-aminolevulinic acid,” Chin. J. Med. Surg. 8, 9–11 (1999) (in Chinese)

[11] [11] Wang, X. L., Wang, H. W., Guo, M. X. and Xu, S. Z., “Treatment of skin cancer and pre-cancer using topical ALA-PDT — A single hospital experience,” Photodiag. Photodyn. Ther. 5, 127–133 (2008).

[12] [12] Braathen, L. R., Szeimies, R. M., Basset-Seguin, N., Bissonnette, R., Foley, P., Pariser, D., Roelandts, R., Wennberg, A. M. and Morton, C. A., “International Society for Photodynamic Therapy in Dermatology, Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. International Society for Photodynamic Therapy in Dermatology, 2005,” J. Am. Acad. Dermatol. 56, 125–143 (2007).

[13] [13] Moloney, F. J. and Collins, P., “Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis,” Br. J. Dermatol. 157, 87–91 (2007).

[14] [14] Schleier, P., Berndt, A., Kolossa, S., Zenk, W., Hyckel, P. and Schultze-Mosgau, S., “Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma,” Photodiag. Photodyn. Ther. 4, 197–201 (2007).

[15] [15] Kaufmann, R., Spelman, L., Weightman, W., Reifenberger, J., Szeimies, R. M., Verhaeghe, E., Kerrouche, N., Sorba, V., Villemagne, H. and Rhodes, L. E., “Multicentre intraindividual randomized trial of topical methyl aminolaevulinatephotodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities,” Br. J. Dermatol. 158, 994–999 (2008).

[16] [16] Tierney, E. P., Eide, M. J., Jacobsen, G. and Ozog, D., “Photodynamic therapy for actinic keratoses: Survey of patient perceptions of treatment satisfaction and outcomes,” J. Cosmet. Laser Ther. 10, 81–86 (2008).

[17] [17] Sotiriou, E., Apalla, Z., Koussidou-Erremonti, T. and Ioannides, D., “Actinic cheilitis treated with one cycle of 5-aminolaevulinic acid-based photodynamic therapy: Report of 10 cases,” Br. J. Dermatol. 159, 261–262 (2008).

[18] [18] Babilas, P., Knobler, R., Hummel, S., Gottschaller, C., Maisch, T., Koller, M., Landthaler, M. and Szeimies, R. M., “Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: A prospective randomized controlled trial,” Br. J. Dermatol. 157, 111–117 (2007).

[19] [19] Rhodes, L. E., de Rie, M. A., Leifsdottir, R., Yu, R. C., Bachmann, I., Goulden, V., Wong, G. A., Richard, M. A., Anstey, A. and Wolf, P., “Fiveyear follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs. surgery for nodular basal cell carcinoma,” Arch. Dermatol. 143, 1131–1136 (2007).

[20] [20] Souza, C. S., Neves,A. B., Fel′ cio, L.A., Ferreira, J., Kurachi, C. and Bagnato, V. S., “Optimized photodynamic therapy with systemic photosensitizer following debulking technique for nonmelanoma skin cancers,” Dermatol. Surg. 33, 194–198 (2007).

[21] [21] Mosterd, K., Thissen, M. R., Nelemans, P., Kelleners-Smeets, N. W., Janssen, R. L., Broekhof, K. G., Neumann, H. A., Steijlen, P. M. and Kuijpers, D. I., “Fractionated 5-aminolaevulinic acidphotodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial,” Br. J. Dermatol. 159, 864–870 (2008).

[22] [22] Piaserico, S., Belloni Fortina, A., Rigotti, P., Rossi, B., Baldan, N., Alaibac, M. and Marchini, F., “Topical photodynamic therapy of actinic keratosis in renal transplant recipients,” Transplant. Proc. 39, 1847–1850 (2007).

[23] [23] Perrett, C. M., McGregor, J. M., Warwick, J., Karran, P., Leigh, I. M., Proby, C. M. and Harwood, C. A., “Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy,” Br. J. Dermatol. 156, 320–328 (2007).

[24] [24] Leman, J. A., Dick, D. C. and Morton, C. A., “Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma,” Clin. Exp. Dermatol. 27, 516–518 (2002).

[25] [25] Edstr¨om, D. W. and Hedblad, M. A., “Long-term follow-up of photodynamic therapy for mycosis fungoides,” Acta. Derm. Venereol. 88, 288–290 (2008).

[26] [26] Nikkels, A. F., Thirion, L., Quatresooz, P. and Pi′erard, G. E., “Photodynamic therapy for cutaneous verrucous carcinoma,” J. Am. Acad. Dermatol. 57, 516–519 (2007).

[27] [27] Raspagliesi, F., Fontanelli, R., Rossi, G., Ditto, A., Solima, E., Hanozet, F. and Kusamura, S., “Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget’s disease of the vulva: A pilot study,” Gynecol. Oncol. 103, 581–586 (2006).

[28] [28] Calzavara-Pinton, P. G., Szeimies, R. M., Ortel, B. and Zane, C., “Photodynamic therapy with systemic administration of photosensitizers in dermatology,” J. Photochem. Photobiol. B: Biol. 36, 225–231 (1996).

[29] [29] Kacerovsk′a, D., Pizinger, K., Majer, F. and Sm′ d, F., “Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract — a pilot study,” Photochem. Photobiol. 84, 779–785 (2008).

[30] [30] Betz, C. S., Rauschning, W., Stranadko, E. P., Riabov, M. V., Albrecht, V., Nifantiev, N. E. and Hopper, C., “Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas,” Lasers Surg. Med. 40, 300–311 (2008).

[31] [31] Taub, A. F., “Photodynamic therapy: Other uses,” Dermatol. Clin. 25, 101–109 (2007).

[32] [32] Murphree, A. L., Cote, M. and Gomer, C. J., “The evolution of photodynamic therapy techniques in the treatment of intraocular tumors,” Photochem. Photobiol. 46, 919–923 (1987).

[33] [33] Battaglia Parodi, M., Da Pozzo, S., Toto, L., Saviano, S. and Ravalico, G., “Photodynamic therapy for choroidal neovascularization associated with choroidal osteoma,” Retina 21, 660–661 (2001).

[34] [34] Blaise, P., Duchateau, E., Comhaire, Y. and Rakic, J. M., “Improvement of visual acuity after photodynamic therapy for choroidal neovascularization in choroidal osteoma,” Acta Ophthalmol. Scand. 83, 515–516 (2005).

[35] [35] Shields, C. L., Materin, M. A., Mehta, S., Foxman, B. T. and Shields, J. A., “Regression of extrafoveal choroidal osteoma following photodynamic therapy,” Arch. Ophthalmol. 126, 135–137 (2008).

[36] [36] Harbour, J. W., “Photodynamic therapy for choroidal metastasis from carcinoid tumor,” Am. J. Ophthalmol. 137, 1143–1145 (2004).

[37] [37] Mauget-Fa¨ysse, M., Gambrelle, J., Quaranta-El Maftouhi, M. and Moullet, I., “Photodynamic therapy for choroidal metastasis from lung adenocarcinoma,” Acta Ophthalmol. Scand. 84, 552–554 (2006).

[38] [38] Isola, V., Pece, A. and Pierro, L., “Photodynamic therapy with verteporfin of choroidal malignancy from breast cancer,” Am. J. Ophthalmol. 142, 885– 887 (2006).

[39] [39] Schuller, D. E., McCaughan Jr, J. S. and Rock, R. P., “Photodynamic therapy in head and neck cancer,” Arch. Otolaryngol. 111, 351–355 (1985).

[40] [40] Zhao, S. P., Tao, Z. D., Xiao, J. Y., Peng, Y. Y., Yang, Y. H., Zeng, Q. S. and Liu, Z. W., “Photoradiation therapy of animal tumors and nasopharyngeal carcinoma,” Ann. Otol. Rhinol. Laryngol. 99, 454–460 (1990).

[41] [41] Copper, M. P., Triesscheijn, M., Tan, I. B., Ruevekamp, M. C. and Stewart, F. A., “Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx,” Clin. Otolaryngol. 32, 185–189 (2007).

[42] [42] Chen, H. M., Yu, C. H., Tsai, T. M., Hsu, Y. C., Kuo, R. C. and Chiang, C. P., “Topical 5- aminolevulinic acid-mediated photodynamic therapy for oral verrucous hyperplasia, oral leukoplakia and oral erythroleukoplakia,” Photodiag. Photodyn. Ther. 4, 44–52 (2007).

[43] [43] Biel, M. A., “Photodynamic therapy and the treatment of head and neck neoplasia,” Laryngoscope 108, 1259–1268 (1998).

[44] [44] Li, L. B., Luo, R. C., Liao, W. J., Zhang, M. J., Luo, Y. L. and Miao, J. X., “Clinical study of Photofrin photodynamic therapy for the treatment of relapse nasopharyngeal carcinoma,” Photodiag. Photodyn. Ther. 3, 266–271 (2006).

[45] [45] Biel, M. A., “Photodynamic therapy treatment of early oral and laryngeal cancers,” Photochem. Photobiol. 83, 1063–1068 (2007).

[46] [46] Biel, M., “Advances in photodynamic therapy for the treatment of head and neck cancers,” Lasers Surg. Med. 38, 349–355 (2006).

[47] [47] Copper, M. P., Tan, I. B., Oppelaar, H., Ruevekamp, M. C. and Stewart, F. A., “Metatetra( hydroxyphenyl) chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck,” Arch. Otolaryngol. Head Neck Surg. 129, 709–711 (2003).

[48] [48] Hopper, C., Kubler, A., Lewis, H., Tan, I., B., Putnam, G. and the Foscan 01 Study Group, “mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma,” Int. J. Cancer. 111, 138–146 (2004).

[49] [49] D’Cruz, A. K., Robinson, M. H. and Biel, M. A., “mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study of 128 patients,” Head Neck. 26, 232–240 (2004).

[50] [50] Diamond, I., Granelli, S. G., McDonagh, A. F., Nielsen, S.,Wilson, C. B. and Jaenicke, R., “Photodynamic therapy of malignant tumours,” Lancet 2, 1175–1177 (1972).

[51] [51] Perria, C., Capuzzo, T., Cavagnaro, G., Datti, R., Francaviglia, N., Rivano, C. and Tercero, V. E., “Fast attempts at the photodynamic treatment of human gliomas,” J. Neurosurg. Sci. 24, 119–129 (1980).

[52] [52] Laws Jr, E. R., Cortese, D. A., Kinsey, J. H., Eagan, R. T. and Anderson, R. E., “Photoradiation therapy in the treatment of malignant brain tumors: A phase I (feasibility) study,” Neurosurgery 9, 672–678 (1981).

[53] [53] Kostron, H., Plangger, C., Fritsch, E. and Maier, H., “Photodynamic treatment of malignant brain tumors,” Wien Klin. Wochenschr. 102, 531–535 (1990).

[54] [54] Muller, P. J. and Wilson, B. C., “Photodynamic therapy for recurrent supratentorial gliomas,” Semin. Surg. Oncol. 11, 346–354 (1995).

[55] [55] Schmidt, M. H., Bajic, D. M., Reichert II, K. W., Martin, T. S., Meyer, G. A. and Whelan, H. T., “Light-emitting diodes as a light source for intraoperative photodynamic therapy,” Neurosurgery 38, 552–556 (1996).

[56] [56] Zimmermann, A., Ritsch-Marte, M. and Kostron, H., “mTHPC-mediated photodynamic diagnosis of malignant brain tumors,” Photochem. Photobiol. 74, 611–616 (2001).

[57] [57] Muller, P. J. and Wilson, B. C., “Photodynamic therapy of brain tumors — a work in progress,” Lasers Surg. Med. 38, 384–389 (2006).

[58] [58] Beck, T. J., Kreth, F. W., Beyer, W., Mehrkens, J. H., Obermeier, A., Stepp, H., Stummer, W. and Baumgartner, R., “Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX,” Lasers Surg. Med. 39, 386–393 (2007).

[59] [59] Stylli, S. S., Kaye, A. H., Macgregor, L., Howes, M. and Rajendra, P., “Photodynamic therapy of high-grade glioma — long term survival,” J. Clin. Neurosci. 12, 389–398 (2005).

[60] [60] Moseley, H., Mclean, C., Hockaday, S. and Eljamel, S., “In vitro light distributions from intracranial PDT balloons,” Photodiag. Photodyn. Ther. 4, 213–220 (2007).

[61] [61] Dougherty, T. J., “Photoradiation therapy for bronchogenic cancer,” Chest. 81, 265–266 (1982).

[62] [62] Usuda, J., Kato, H., Okunaka, T., Furukawa, K., Tsutsui, H., Yamada, K., Suga, Y., Honda, H., Nagatsuka, Y., Ohira, T., Tsuboi, M. and Hirano, T., “Photodynamic therapy (PDT) for lung cancers,” J. Thorac. Oncol. 1, 489–493 (2006).

[63] [63] Corti, L., Toniolo, L., Boso, C., Colaut, F., Fiore, D., Muzzio, P. C., Koukourakis, M. I., Mazzarotto, R., Pignataro, M., Loreggian, L. and Sotti, G., “Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma,” Lasers Surg. Med. 39, 394–402 (2007).

[64] [64] Moghissi, K. and Dixon, K., “Update on the current indications, practice and results of photodynamic therapy (PDT) in early central lung cancer (ECLC),” Photodiag. Photodyn. Ther. 5, 10–18 (2008).

[65] [65] Usuda, J., Tsutsui, H., Honda, H., Ichinose, S., Ishizumi, T., Hirata, T., Inoue, T., Ohtani, K., Maehara, S., Imai, K., Tsunoda, Y., Kubota, M., Ikeda, N., Furukawa, K., Okunaka, T. and Kato, H., “Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy,” Lung Cancer 58, 317–323 (2007).

[66] [66] Kato, H., Konaka, C., Ono, J., Kawate, N., Nishimiya, K., Shinohara, H., Saito, M., Sakai, H., Noguchi, M. and Kito, T., “Preoperative laser photodynamic therapy in combination with operation in lung cancer,” J. Thorac. Cardiovasc. Surg. 90, 420–429 (1985).

[67] [67] Mortman, K. D. and Frankel, K. M., “Pulmonary resection after successful downstaging with photodynamic therapy,” Ann. Thorac. Surg. 82, 722–724 (2006).

[68] [68] Litle, V. R., Christie, N. A., Fernando, H. C., Buenaventura, P. O., Ferson, P. F. and Luketich, J. D., “Photodynamic therapy for endobronchial metastases from nonbronchogenic primaries,” Ann. Thorac. Surg. 76, 370–375 (2003).

[69] [69] Magro, C. M., Abbas, A. E. and Ross Jr, P., “The application of photodynamic therapy in the treatment of metastatic endobronchial disease,” Lasers Surg. Med. 38, 376–383 (2006).

[70] [70] Okunaka, T., Kato, H., Tsutsui, H., Ishizumi, T., Ichinose, S. and Kuroiwa, Y., “Photodynamic therapy for peripheral lung cancer,” Lung Cancer 43, 77–82 (2004).

[71] [71] Pass, H. I., Tochner, Z., DeLaney, T., Smith, P., Friauf, W., Glatstein, E. and Travis, W., “Intraoperative photodynamic therapy for malignant mesothelioma,” Ann. Thorac. Surg. 50, 687–688 (1990).

[72] [72] Lofgren, L., Larsson,M., Thaning, L. and Hallgren, S., “Transthoracic endoscopic photodynamic treatment of malignant mesothelioma,” Lancet 337, 359 (1991).

[73] [73] Ris, H. B., Altermatt, H. J., Inderbitzi, R., Hess, R., Nachbur, B., Stewart, J. C., Wang, Q., Lim, C. K., Bonnett, R. and Berenbaum, M. C., “Photodynamic therapy with chlorins for diffuse malignant mesothelioma: Initial clinical results,” Br. J. Cancer 64, 1116–1120 (1991).

[74] [74] Hahn, S. M., Smith, R. P. and Friedberg, J., “Photodynamic therapy for mesothelioma,” Curr. Treat. Options Oncol. 2, 375–383 (2001).

[75] [75] Friedberg, J. S., Mick, R., Stevenson, J., Metz, J., Zhu, T., Buyske, J., Sterman, D. H., Pass, H. I., Glatstein, E. and Hahn, S. M., “A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma,” Ann. Thorac. Surg. 75, 952–959 (2003).

[76] [76] Huang, Z., Chen, Q., Shakil, A., Chen, H., Beckers, J., Shapiro, H. and Hetzel, F. W., “Hyperoxygenation enhances the tumor cell killing of Photofrin-mediated photodynamic therapy,” Photochem. Photobiol. 78, 496–502 (2003).

[77] [77] Matzi, V., Maier, A., Sankin, O., Lindenmann, J., Woltsche, M., Smolle, J. and F. Smolle- J¨uttner, “Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: Clinical experience,” Photodiag. Photodyn. Ther. 1, 57–64 (2004).

[78] [78] Sperduto, P. W., DeLaney, T. F., Thomas, G., Smith, P., Dachowski, L. J., Russo, A., Bonner, R. and Glatstein, E., “Photodynamic therapy for chest wall recurrence in breast cancer,” Int. J. Radiat. Oncol. Biol. Phys. 21, 441–446 (1991).

[79] [79] Wyss, P., Schwarz, V., Dobler-Girdziunaite, D., Hornung, R., Walt, H., Degen, A. and Fehr, M., “Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer,” Int. J. Cancer 93, 720–724 (2001).

[80] [80] Cuenca, R. E., Allison, R. R., Sibata, C. and Downie, G. H., “Breast cancer with chest wall progression: Treatment with photodynamic therapy,” Ann. Surg. Oncol. 11, 322–327 (2004).

[81] [81] D’Hallewin, M. A., Kochetkov, D., Viry-Babel, Y., Leroux, A., Werkmeister, E., Dumas, D., Gr¨afe, S., Zorin, V., Guillemin, F. and Bezdetnaya, L., “Photodynamic therapy with intratumoral administration of Lipid-Based mTHPC in a model of breast cancer recurrence,” Lasers Surg. Med. 40, 543–549 (2008).

[82] [82] Allison, R. R., Sibata, C., Downie, G. H. and Cuenca, R. E., “Photodynamic therapy of the intact breast,” Photodiag. Photodyn. Ther. 3, 139– 146 (2006).

[83] [83] Hayata, Y., Kato, H., Okitsu, H., Kawaguchi, M. and Konaka, C., “Photodynamic therapy with hematoporphyrin derivative in cancer of the upper gastrointestinal tract,” Semin. Surg. Oncol. 1, 1–11 (1985).

[84] [84] McCaughan Jr, J. S., “Overview of experiences with photodynamic therapy for malignancy in 192 patients,” Photochem. Photobiol. 46, 903–909 (1987).

[85] [85] Barr, H., Krasner, N., Boulos, P. B., Chatlani, P. and Bown, S. G., “Photodynamic therapy for colorectal cancer: A quantitative pilot study,” Br. J. Surg. 77, 93–96 (1990).

[86] [86] Jin, M. L., Yang, B. Q., Zhang, W. and Ren, P., “Review of photodynamic therapy for gastrointestinal tumours in the past 6 years in China,” J. Photochem. Photobiol. B: Biol. 7, 87–92 (1990).

[87] [87] Patrice, T., Foultier, M. T., Yactayo, S., Adam, F., Galmiche, J. P., Douet, M. C. and Le Bodic, L., “Endoscopic photodynamic therapy with hematoporphyrin derivative for primary treatment of gastrointestinal neoplasms in inoperable patients,” Dig. Dis. Sci. 35, 545–552 (1990).

[88] [88] Mackenzie, G. D., Jamieson, N. F., Novelli, M. R., Mosse, C. A., Clark, B. R., Thorpe, S. M., Bown, S. G. and Lovat, L. B., “How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett’s esophagus,” Lasers Med. Sci. 23, 203–210 (2008).

[89] [89] Panjehpour,M., Overholt, B. F., Phan, M. N. and Haydek, J. M., “Optimization of light dosimetry for photodynamic therapy of Barrett’s esophagus: Efficacy vs. incidence of stricture after treatment,” Gastrointest. Endosc. 61, 13–18 (2005).

[90] [90] Prasad, G. A., Wang, K. K., Buttar, N. S., Wongkeesong, L. M., Lutzke, L. S. and Borkenhagen, L. S., “Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett’s esophagus,” Gastrointest. Endosc. 65, 60–66 (2007).

[91] [91] Yachimski, P., Puricelli, W. P. and Nishioka, N. S., “Patient predictors of esophageal stricture development after photodynamic therapy,” Clin. Gastroenterol. Hepatol. 6, 302–308 (2008).

[92] [92] Prasad, G. A., Wang, K. K., Halling, K. C., Buttar, N. S., Wongkeesong, L. M., Zinsmeister, A. R., Brankley, S. M., Fritcher, E. G., Westra, W. M., Krishnadath, K. K., Lutzke, L. S. and Borkenhagen, L. S., “Utility of biomarkers in prediction of response to ablative therapy in Barrett’s esophagus,” Gastroenterology 135, 370–379 (2008).

[93] [93] Ortner, M. A., “Photodynamic therapy in cholangiocarcinoma: An overview,” Photodiag. Photodyn. Ther. 1, 85–92 (2004).

[94] [94] Prasad, G. A.,Wang, K. K., Baron, T. H., Buttar, N. S., Wongkeesong, L. M., Roberts, L. R., LeRoy, A. J., Lutzke, L. S. and Borkenhagen, L. S., “Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma,” Clin. Gastroenterol. Hepatol. 5, 743–748 (2007).

[95] [95] Kahaleh, M., Mishra, R., Shami, V. M., Northup, P. G., Berg, C. L., Bashlor, P., Jones, P., Ellen, K., Weiss, G. R., Brenin, C. M., Kurth, B. E., Rich, T. A., Adams, R. B. and Yeaton, P., “Unresectable cholangiocarcinoma: Comparison of survival in biliary stenting alone versus stenting with photodynamic therapy,” Clin. Gastroenterol. Hepatol. 6, 290–297 (2008).

[96] [96] Saito, H., Takada, T., Miyazaki, M., Miyakawa, S., Tsukada, K., Nagino, M., Kondo, S., Furuse, J., Tsuyuguchi, T., Kimura, F., Yoshitomi, H., Nozawa, S., Yoshida, M., Wada, K., Amano, H., Miura, F., Japanese Association of Biliary Surgery, Japanese Society of Hepato- Biliary-Pancreatic Surgery and Japan Society of Clinical Oncology, “Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas,” J. Hepatobiliary Pancreat. Surg. 15, 63–68 (2008).

[97] [97] Witzigmann, H., Berr, F., Ringel, U., Caca, K., Uhlmann, D., Schoppmeyer, K., Tannapfel, A., Wittekind, C., Mossner, J., Hauss, J. and Wiedmann, M., “Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: Palliative photodynamic therapy plus stenting is comparable to r1/r2 resection,” Ann. Surg. 244, 230–239 (2006).

[98] [98] Pereira, S. P., Ayaru, L., Rogowska, A., Mosse, A., Hatfield, A. R. and Bown, S. G., “Photodynamic therapy of malignant biliary structures using mesotetrahydroxyphenylchlorin,” Eur. J. Gastroenterol. Hepatol. 19, 479–485 (2007).

[99] [99] Wang, L. W., Li, L. B., Li, Z. S., Chen, Y. K., Hetzel, F. W. and Huang, Z., “Self-expandable metal stents and trans-stent light delivery: Are stents and PDT compatible ” Lasers Surg. Med. 40, 651–659 (2008).

[100] [100] Huang, Z., Xu, H., Meyers, A. D., Musani, A. I., Wang, L., Tagg, R., Barqawi, A. B. and Chen, Y. K., “Photodynamic therapy for treatment of solid tumors — potential and technical challenges,” Tech. Cancer Res. Treat. 7, 309–320 (2008).

[101] [101] Bown, S. G., Rogowska, A. Z., Whitelaw, D. E., Lees, W. R., Lovat, L. B., Ripley, P., Jones, L., Wyld, P., Gillams, A. and Hatfield, A. W., “Photodynamic therapy for cancer of the pancreas,” Gut. 50, 549–557 (2002).

[102] [102] Huang, Z., “Photodynamic therapy in China: over 25 years of unique clinical experience: part two — Clinical experience,” Photodiag. Photodyn. Ther. 3, 71–84 (2006).

[103] [103] Zeng, C. Y., Yang, D., Huang, P., Zhang, J. H., Chen, J. and Lu, G. R., “Long-term follow-up results of 70 Liver cancer cases received ultrasound guided percutaneous PDT,” Chin. J. Laser Med. Surg. 9, 146–149 (2000) (in Chinese)

[104] [104] Kujundzi′c, M., Vogl, T. J., Stimac, D., Rustemovi ′c, N., Hsi, R. A., Roh, M., Katici′c, M., Cuenca, R., Lustig, R. A. andWang, S., “A phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer,” J. Surg. Oncol. 96, 518–524 (2007).

[105] [105] Kelly, J. F., Snell, M. E. and Berenbaum, M. C., “Photodynamic destruction of human bladder carcinoma,” Br. J. Cancer 31, 237–244 (1975).

[106] [106] Manyak, M. J. and Ogan, K., “Photodynamic therapy for refractory superficial bladder cancer: Longterm clinical outcomes of single treatment using intravesical diffusion medium,” J. Endourol. 17, 633–639 (2003).

[107] [107] Waidelich, R., Stepp, H., Baumgartner, R., Weninger, E., Hofstetter, A. and Kriegmair, M., “Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer,” J. Urol. 165, 1904–1907 (2001).

[108] [108] Berger, A. P., Steiner, H., Stenzl, A., Akkad, T., Bartsch, G. and Holtl, L., “Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: A single-center study,” Urology 61, 338–341 (2003).

[109] [109] Kamuhabwa, A., Agostinis, P., Ahmed, B., Landuyt, W., van Cleynenbreugel, B., van Poppel, H. and de Witte, P., “Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder,” Photochem. Photobiol. Sci. 3, 772–780 (2004).

[110] [110] Marti, A., Jichlinski, P., Lange, N., Ballini, J. P., Guillou, L., Leisinger, H. J. and Kucera, P., “Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer,” J. Urol. 170, 428–432 (2003).

[111] [111] Nathan, T. R.,Whitelaw, D. E., Chang, S. C., Lees, W. R., Ripley, P. M., Payne, H., Jones, L., Parkinson, M. C., Emberton, M., Gillams, A. R., Mundy, A. R. and Bown, S. G., “Photodynamic therapy for prostate cancer recurrence after radiotherapy: A phase I study,” J. Urol. 168, 1427–1432 (2002).

[112] [112] Zaak, D., Sroka, R., H¨oppner, M., Khoder, W., Reich, O., Tritschler, St., Muschter, R., Kn¨uchel, R. and Hofstetter, A., “Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer — preliminary results,” Med. Laser Appl. 18, 91–95 (2003).

[113] [113] Moore, C. M., Nathan, T. R., Lees, W. R., Mosse, C.A., Freeman, A., Emberton,M. andBown, S. G., “Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer,” Laser Surg. Med. 38, 356–363 (2006).

[114] [114] Du, K. L., Mick, R., Busch, T. M., Zhu, T. C., Finlay, J. C., Yu, G., Yodh, A. G., Malkowicz, S. B., Smith, D., Whittington, R., Stripp, D. and Hahn, S. M., “Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer,” Laser Surg. Med. 38, 427–434 (2006).

[115] [115] Trachtenberg, J., Bogaards, A., Weersink, R. A., Haider, M. A., Evans, A., McCluskey, S. A., Scherz, A., Gertner, M. R., Yue, C., Appu, S., Aprikian, A., Savard, J., Wilson, B. C. and Elhilali, M., “Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: Assessment of safety and treatment response,” J. Urol. 178, 1974–1979 (2007).

[116] [116] Weersink, R. A., Bogaards, A., Gertner, M., Davidson, S. R. H., Zhang, K., Netchev, G., Trachtenberg, J. and Wilson, B. C., “Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: Clinical experience and practicalities,” J. Photochem. Photobiol. B. Biol. 79, 211–222 (2005).

[117] [117] Zhu, T. C. and Finlay, J. C., “Prostate PDT dosimetry,” Photodiag. Photodyn. Ther. 3, 234–246 (2006).

[118] [118] Dole, K. C., Chen, Q., Hetzel, F. W., Whalen, L. R., Blanc, D. and Huang, Z., “Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model,” Photomed. Laser Surg. 23, 172–176 (2005).

[119] [119] Huang, Z., Chen, Q., Dole, K. C., Barqawi, A. B., Chen, Y. K., Blanc, D., Wilson, B. C. and Hetzel, F. W., “The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues — in vivo study in a canine model,” Photochem. Photobiol. Sci. 6, 1318–1324 (2007).

[120] [120] Huang, Z., Chen, Q., Luck, D., Beckers, J., Wilson, B. C., Trncic, N., LaRue, S. M., Blanc, D. and Hetzel, F.W., “Studies of a vascular-acting photosensitizer, Pdbacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer,” Laser Surg. Med. 36, 390–397 (2005).

[121] [121] Eggener, S. E. and Coleman, J. A., “Focal treatment of prostate cancer with vasculartargeted photodynamic therapy,” Scientific World J. 3, 963–973 (2008).

[122] [122] Muroya, T., Suehiro, Y., Umayahara, K., Akiya, T., Iwabuchi, H., Sakunaga, H., Sakamoto, M., Sugishita, T. and Tenjin, Y., “Photodynamic therapy (PDT) for early cervical cancer,” Cancer Chemother. [Gan To Kagaku Ryoho] 23, 47–56 (1996) (in Japanese).

[123] [123] Allison, R. R., Cuenca, R., Downie, G. H., Randall, M., Bagnato, V. and Sibata, C., “PD/PDT for gynecological disease: A clinical review,” Photodiag. Photodyn. Ther. 2, 51–63 (2005).

[124] [124] Barnett, A. A., Haller, J. C., Cairnduff, F., Lane, G., Brown, S. B. and Roberts, D. J. H., “A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia,” Int. J. Cancer 103, 829–832 (2003).

[125] [125] Fehr, M. K., Hornung, R., Degen, A., Schwarz, V. A., Fink, D., Haller, U. and Wyss, P., “Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid,” Laser Surg. Med. 30, 273–279 (2002).

[126] [126] Campbell, S. M. and Curnow, A., “Extensive vulval intraepithelial neoplasia treated with a new regime of systemic photodynamic therapy using meta-tetrahydroxychlorin (Foscan),” J. Eur. Acad. Dermatol. Venereol. 22, 502–503 (2008).

[127] [127] Paoli, J., Ternesten Bratel, A., L¨owhagen, G. B., Stenquist, B., Forslund, O. and Wennberg, A. M., “Penile intraepithelial neoplasia: Results of photodynamic therapy,” Acta Derm. Venereol. 86, 418– 421 (2006).

[128] [128] Corti, L., Tomio, L., Maluta, S., Minucci, D., Fontana, M., Cittar, H. and Calzavara, F., “Recurring gynaecologic cancer treated with photodynamic therapy,” Photochem. Photobiol. 46, 949–952 (1987).

[129] [129] Koren, H. and Alth, G., “Photodynamic therapy in gynaecologic cancer,” J. Photochem. Photobiol. B 36, 189–191 (1996).

[130] [130] Wierrani, F., Fiedler, D., Grin, W., Henry, M., Dienes, E., Gharehbaghi, K., Krammer, B. and Gr¨unberger, W., “Clinical effect of mesotetrahydroxyphenylchlorine based photodynamic therapy in recurrent carcinoma of the ovary: Preliminary results,” Br. J. Obstet. Gynaecol. 104, 376–378 (1997).

[131] [131] Tochner, Z., Mitchell, J. B., Smith, P., Harrington, F., Glatstein, E., Russo, D. and Russo, A., “Photodynamic therapy of ascites tumours within the peritoneal cavity,” Br. J. Cancer 53, 733–736 (1986).

[132] [132] DeLaney, T. F., Sindelar, W. F., Tochner, Z., Smith, P. D., Friauf, W. S., Thomas, G., Dachowski, L., Cole, J. W., Steinberg, S. M. and Glatst